Polypeptide inhibitor modified with polyethylene glycol for inhibiting vascular endothelial growth factor receptors 2 tyrosine kinase and application thereof.

Abstract

The invention relates to the field of medicines and particularly relates to polypeptide for inhibiting vascular endothelial growth factor receptors 2 tyrosine kinase and preventing and treating the rheumatoid arthritis. After the polypeptide is modified with polyethylene glycol and the sequence of the polypeptide is Mpeg-SC10k-Val-Cys-CyS-Ser-Thr-Arg-Glu which is an entirely-new sequence. The polypeptide can be used for treating the rheumatoid arthritis and has potential new-medicine development value.

Description

Technical field: [0001] The invention relates to the field of medicine, in particular to a vascular endothelial growth factor receptor 2 tyrosine kinase polypeptide inhibitor for preventing and treating rheumatoid arthritis. Background technique: [0002] Rheumatoid arthritis (RA) is the most common clinical inflammatory joint disease and one of the main disabling factors. It is about 0.5%-1.0% in the world, and the incidence of RA is about 0.4% in my country. RA can occur at any age, and the incidence rate increases with age. The high-incidence age of women is 45-55 years old, and gender is closely related to the incidence of RA, with a male-to-female ratio of about 1:3. [0003] Neovascularization, under normal physiological conditions, is highly regulated and is an essential process in reproduction, embryonic development, tissue repair and wound healing. Angiogenesis also occurs in various pathological conditions, such as RA. In the pathological process of RA, angio...

AI Technical Summary

Problems solved by technology

The research on PEG modification of synthetic small molecule peptides started late, but it has attracted the attention of many researchers